The two-way ANOVA revealed a main effect of inosine treatment [F(1, 25)=6

The two-way ANOVA revealed a main effect of inosine treatment [F(1, 25)=6. 67, g <0. 05], wortmannin treatment [F(1, 25)=16. 78, p <0. 001], and inosine treatment wortmannin treatment interaction [F(1, 25)=7. 49, g <0. 01]. induced a synergic antidepressant-like effect. None of the remedies altered locomotor activity of mice. Moreover, 24 h after a single admin of inosine (10 mg/kg, i. g. ), CREB phosphorylation was increased in the hippocampus. Our findings offered new proof that the antidepressant-like effect of inosine in BAY-850 the TST involves the activation of PKA, PI3K/Akt, ERK1/2, and CaMKII and the inhibition of GSK-3. These results contribute to the comprehension in the mechanisms fundamental the purinergic system modulation and show the intracellular signaling pathways involved in the antidepressant-like effect of inosine in a preclinical test of depression. Keywords: Inosine, Major depression, Signaling pathways, Protein kinases, CREB == Introduction == Major depressive disorder (MDD) is a severe public health issue, responsible for a profound adverse impact on the product quality life of patients and a socioeconomic burden [13]. In spite of all the attempts towards elucidating the neurochemical alterations found in depressive individuals, there is continue to a lack of understanding about the molecular basis behind this disorder. The present pharmacological therapy for MDD is not completely effective since two thirds of individuals did not react to the 1st prescribed drug and most antidepressants are associated with several side effects [4, 5]. A number of clinical and preclinical studies have demonstrated the involvement of purinergic system in psychiatric disorders including MDD [68]. Accordingly, adenosine receptors are able to control cellular excitability and modulate several neurotransmission systems involved with behavioral, neurochemical, and endocrine alterations associated with MDD, such as dopaminergic, serotoninergic, and glutamatergic systems [9, 10]. In addition , preclinical data have demostrated that modulation of adenosine receptors induces antidepressant-like effects in behavioral despair versions in mice [1114] and prevents depressive and anhedonic behavior of mice submitted to persistent unpredictable tension [6]. Also, an increase in adenosine A2Areceptor expression in hippocampal synapses was found in a depression-prone mouse stress, and rats overexpressing adenosine A2Areceptors show a depressive, anhedonic, and anxious phenotype [15, 16]. Inosine is an endogenous purine nucleoside created by cleavage of adenosine in a reaction catalyzed by adenosine deaminase (ADA) [17]. Although few studies have dedicated to the physiological roles of inosine, there exists a growing physique of proof suggesting this nucleoside provides significant biological effects. It has been suggested that inosine elicits neuroprotective effects in neurons and astrocytes subjected to hypoxia, glucose-oxygen deprivation, and oxidative damage [18, 19]; stimulates neurite outgrowth in vitro [20]; and induces axonal outgrowth in vivo and in vitro studies [2125]. Moreover, systemic administration of inosine causes antinociceptive, antiallodynic, and antihyperalgesic effects in mice [26, 27]. Evidence coming from clinical studies has suggested antioxidant and protective houses of inosine in multiple sclerosis and Parkinsons disease patients [2830]. Indeed, many of the behavioral and neuroprotective effects of inosine were associated with its ability to interact with distinct adenosine receptors. The antinociceptive effect of inosine involves adenosine A1receptor direct activation, suggesting that this nucleoside can become adenosine A1receptor BAY-850 agonist [31]. Also, it was recently demonstrated that inosine can situation and switch on A2Aadenosine receptor [32]. Several works have shown that inosine provides Rabbit Polyclonal to OR4A15 immunomodulatory effects through adenosine A3receptor activation [3335]. It was previously reported by our group that intraperitoneal (i. p. ) administration of inosine reduces the immobility time in behavioral despair models of depression by a mechanism determined by the activation of adenosine A1and A2Areceptors [36]. This antidepressant potential was further proved by Muto et ing. [20], showing that chronic admin of inosine prevented the depressive-like effect in the pressured swimming check (FST) and the decreased mobile BAY-850 proliferation in the dentate gyrus in mice subjected to persistent unpredictable tension. A single admin of inosine was also able to considerably increase extracellular-regulated protein kinase (ERK) phosphorylation and the manifestation of brain-derived neurotrophic aspect (BDNF) in mouse hippocampus. Furthermore, the inosine-induced boost on BDNF mRNA was partially avoided by the pretreatment with adenosine A1receptor antagonist DPCPX, suggesting that adenosine A1receptor activation could be involved in the increase of BDNF manifestation induced by inosine with this model. Activation of different kinases can impact cyclic adenosine monophosphatate (cAMP) response-binding component protein (CREB) by phosphorylation at Ser-133, resulting in manifestation of protein related to mobile survival and neuroplasticity such as BDNF [37, 38]. It is widely recognized that changes in brain levels.